Kubota Pharmaceutical Holdings Co., Ltd.
Kubota Pharmaceutical Holdings Co., Ltd. Announcement of Start of Final Formulation Manufacturing of Emixstat Hydrochloride (Retakubo) by Consolidated Subsidiary
Kubota Vision has begun manufacturing the final formulation of Retakubo, targeting the French market. Preparations for supply via Compassionate Use/Access (AAC) are underway, and ANSM approval is required. The impact on financial results is expected to be minimal, with further disclosures if additional progress occurs.
Key Figures
- Start of final formulation manufacturing of Retakubo (date unknown)
- Start of GMP-compliant active pharmaceutical ingredient manufacturing (date unknown)
- ANSM approval requirement (individual application)
AI要約
News Summary
Kubota Vision, a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., has commenced manufacturing the final formulation (oral tablets) of Retakubo under Compassionate Use/Access (AAC) authorization in France. GMP-compliant active pharmaceutical ingredient manufacturing has already started, and the initiation of final formulation manufacturing advances the program to the next stage. Under the supply and license agreement with KÔL, preparations continue toward enabling supply in France, including regulatory approval procedures and distribution readiness.
Investor Impact and Outlook
The start of final formulation manufacturing represents a significant step toward providing the drug to patients via AAC; however, because individual application approval by ANSM is required, the near-term impact on financial results is expected to be minor. Kubota Vision will continue to work with KÔL on regulatory matters for supply realization in France and intends to disclose future progress as appropriate.
Kubota Pharmaceutical Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR